Content deleted Content added
wikilinks |
templates |
||
(29 intermediate revisions by 11 users not shown) | |||
Line 1:
{{Short description|Combination drug}}
{{Use American English|date=July 2020}}
{{Use dmy dates|date=May 2020}}
{{cs1 config |name-list-style=vanc |display-authors=6}}
{{Infobox drug
| drug_name = ▼
| type = combo
| image =
Line 9 ⟶ 11:
| width2 =
| alt2 =
| caption =
<!-- Combo data -->
Line 16 ⟶ 18:
| component2 = Estradiol
| class2 = [[Estrogen (medication)|Estrogen]]
| component3 =
| class3 = [[Progestogen (medication)|Progestin]]
<!-- Clinical data -->
| pronounce =▼
| tradename = Oriahnn
| Drugs.com = {{Drugs.com|ppa|elagolix-estradiol-and-norethindrone}}
| MedlinePlus = a620042
| DailyMedID = Oriahnn
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_AU_comment =
| pregnancy_category=
| routes_of_administration = [[Oral administration|By mouth]]▼
▲| routes_of_administration = By mouth
|
<!-- Legal status -->
Line 55 ⟶ 48:
| legal_UK_comment =
| legal_US = Rx-only
| legal_US_comment = <ref name="Oriahnn FDA label">{{cite web | title=Oriahnn- elagolix and estradiol and norethisterone kit | website=DailyMed | url=https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=99f6eee7-7e52-6999-7eb8-488d06dd1710 | access-date=3 August 2021}}</ref>
| legal_UN = <!-- N I, II, III, IV / P I, II, III, IV -->
| legal_UN_comment =
Line 61 ⟶ 54:
<!-- Identifiers -->
| PubChem =
| IUPHAR_ligand =
| DrugBank =
| ChemSpiderID =
|
| ChEBI =
| ChEMBL =
Line 77 ⟶ 66:
}}
'''Elagolix/estradiol/
The most common side effects include hot flushes (sudden feelings of warmth), headache, fatigue and irregular vaginal bleeding.<ref name="FDA PR" />
Line 84 ⟶ 73:
Fibroids are benign (non-cancerous) muscle tumors of the uterus that can cause heavy menstrual bleeding, pain, bowel or bladder problems and infertility.<ref name="FDA PR" /> Some women may not experience any symptoms, but many do, including heavy bleeding with periods.<ref name="FDA PR" /> Fibroids can occur at any age but are most common in women 35 to 49 years of age.<ref name="FDA PR" /> They typically resolve after [[menopause]] but are a leading reason for [[hysterectomy]] (surgical removal of the uterus) in the United States when they cause severe symptoms.<ref name="FDA PR" />
Elagolix/estradiol/
== Adverse effects ==
Elagolix/estradiol/
The drug label for the combination includes a boxed warning about the risk of vascular events (strokes) and [[Thrombosis|thrombotic]] or [[thromboembolic]] disorders (blood clots), especially in women at increased risk for these events.<ref name="FDA PR" />
== History ==
Elagolix/estradiol/
The efficacy of elagolix/estradiol/
The approval of Oriahnn was granted to AbbVie Inc.<ref name="FDA PR" />
Line 102 ⟶ 91:
== External links ==
* {{ClinicalTrialsGov|NCT02654054|Efficacy and Safety of Elagolix in Combination With Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women}}
* {{ClinicalTrialsGov|NCT02691494|Efficacy and Safety of Elagolix in Combination With Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women (Replicate Study)}}
{{Portal bar
{{Authority control}}
{{DEFAULTSORT:Elagolix Estradiol
[[Category:Drugs developed by AbbVie]]
[[Category:
[[Category:
[[Category:Estrogens]]
[[Category:GnRH antagonists]]
|